BioCentury
ARTICLE | Company News

GUB Unternehmensbeteiligungen GmbH & Co. KGaA, VC Fonds Berlin GmbH, BioGenes deal

November 23, 2015 8:00 AM UTC

Immunoassay and antibody developer BioGenes bought out all outstanding shares of the company from investors GUB Unternehmensbeteiligungen and VC Fonds for an undisclosed sum. GUB and BioGenes declined...